Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28849254 | 0.80 | PSMB8 (0.67) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL30874518 | 0.80 | PSMB8 (0.67) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL7902133 | 0.79 | PSMB8 (0.65) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL5030198 | 0.79 | PSMB8 (0.65) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL10574548 | 0.79 | PSMB8 (0.65) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL23452413 | 0.79 | PSMB8 (1.00) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL969167 | 0.75 | ALDH1A1 (0.66) | SMN1; SMN2ALDH1A1MAPTGAALMNA | |
| SCHEMBL11709639 | 0.75 | PSMB8 (0.59) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL22127190 | 0.75 | ALDH1A1 (0.59) | PSMB8SMN1; SMN2ALDH1A1MAPTGAA | |
| Hydrochloric Acid SCHEMBL28787382 | 0.73 | ALDH1A1 (0.63) | SMN1; SMN2ALDH1A1MAPTGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408829-B1 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | PROMEGA CORP (US) | 2025-11-05 | — | — | EP | disclosed |
| EP-4408829-A1 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | PROMEGA CORPORATION (US) | 2024-08-07 | — | — | EP | disclosed |
| US-11912696-B2 | Compounds and methods for detection of nitric oxide | PROMEGA CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230117418-A1 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | PROMEGA CORPORATION | 2023-04-20 | — | — | US | disclosed |
| WO-2023056447-A1 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | PROMEGA CORPORATION (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-2388254-B1 | Bioluminescent protease assay | PROMEGA CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2614059-B1 | METHODS FOR ASSAYING ENZYME ACTIVITIES | PROMEGA CORP (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8962266-B2 | Methods for assaying enzyme activities | PROMEGA CORPORATION (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140099655-A1 | METHODS FOR ASSAYING ENZYME ACTIVITIES | PROMEGA CORPORATION (US) | 2014-04-10 | — | — | US | disclosed |
| US-8632992-B2 | Methods for assaying enzyme activities | PROMEGA CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2388254-A1 | Bioluminescent protease assay | Promega Corporation (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100249427-A1 | BIOLUMINESCENT PROTEASE ASSAY | PROMEGA CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| US-7666987-B2 | Bioluminescent caspase assay compounds | PROMEGA CORPORATION (US) | 2010-02-23 | — | — | US | disclosed |
| US-7384758-B2 | Bioluminescent protease assay with modified aminoluciferin or derivatives thereof | PROMEAGA CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7148030-B2 | Bioluminescent protease assay | PROMEGA CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060183177-A1 | Bioluminescent protease assay | PROMEGA CORPORATION | 2006-08-17 | — | — | US | disclosed |
| US-20060121546-A1 | Bioluminescent protease assay | PROMEGA CORPORATION | 2006-06-08 | — | — | US | disclosed |
| EP-1472238-A1 | BIOLUMINESCENT PROTEASE ASSAY | PROMEGA CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030211560-A1 | Bioluminescent protease assay | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2003-11-13 | — | — | US | disclosed |
| WO-2003066611-A1 | BIOLUMINESCENT PROTEASE ASSAY | PROMEGA CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117418-A1 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | NOS2, NOS3, NOS1 | PSMB8 3637/4885SMN1; SMN2 2865/4885ALDH1A1 375/4885 |
| US-11912696-B2 | Compounds and methods for detection of nitric oxide | NOS2, NOS3, NOS1 | PSMB8 3637/4885SMN1; SMN2 2865/4885ALDH1A1 375/4885 |
| US-20060121546-A1 | Bioluminescent protease assay | PRSS1, TMPRSS15, TPSAB1 | PSMB8 1286/4885SMN1; SMN2 2800/4885ALDH1A1 2676/4885 |
| US-20100249427-A1 | BIOLUMINESCENT PROTEASE ASSAY | PRSS1, TMPRSS15, TPSAB1 | PSMB8 1286/4885SMN1; SMN2 2800/4885ALDH1A1 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.